Helen Sabzevari, PhD, President and CEO of Precigen, discusses the barriers to implementing cell and gene therapies that impede the accessibility and implementation of these precision medicines. Dr. Sabzevari also explains how key cell and gene therapy platforms and tools can provide safety measures, such as guardrails to cellular toxicity, and address cost by offering “off-the-shelf” efficient gene delivery vectors that can be used on-site, cutting out centralized manufacturing.
Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.
Produced by Bill Levine
Hosted by Jonathan D. Grinstein, PhD
Music provided by Artem Hramushkin
Audio mixed and mastered by Jason Mack
Hosted on Acast. See acast.com/privacy for more information.
Behind the Breakthroughs